Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...

A secondary analysis of a large trial shows that exposure to the HIV drug abacavir is linked to an elevated risk for major ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

In early 2025, the US decision to halt foreign aid for HIV/AIDS programs triggered global concerns about a potential ...

While the National Treasury has released R700m, the Bill and Melinda Gates Foundation and the Wellcome Trust will ...

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

National Treasury has allocated R753 million to the Department of Health -- under Section 16 of the Public Finance Management ...

Lower-income countries will gain access to a "game-changing" HIV prevention drug with a new deal signed between US ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Under the agreement, Gilead will supply enough doses of its Lenacapavir drug to reach up to two million people over three ...

Several Midwestern Cities have been designated as HIV “hotspots” due to the rising number of new cases; and the South ...

People living with HIV face unique oral health challenges that require special attention and care. The virus's impact on the ...